Ruef J - Search Results

1

Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.

Moser M, Bertram U, Peter K, Bode C, Ruef J. Moser M, et al. Among authors: ruef j. J Cardiovasc Pharmacol. 2003 Apr;41(4):586-92. doi: 10.1097/00005344-200304000-00011. J Cardiovasc Pharmacol. 2003. PMID: 12658060

2

Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.

Bertram U, Moser M, Peter K, Kuecherer HF, Bekeredjian R, Straub A, Nordt TK, Bode C, Ruef J. Bertram U, et al. Among authors: ruef j. J Thromb Thrombolysis. 2002 Dec;14(3):197-203. doi: 10.1023/a:1025044625487. J Thromb Thrombolysis. 2002. PMID: 12913399

3

Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.

Nordt TK, Moser M, Kohler B, Ruef J, Peter K, Kübler W, Bode C. Nordt TK, et al. Among authors: ruef j. Thromb Haemost. 1998 Dec;80(6):881-6. Thromb Haemost. 1998. PMID: 9869154

4

A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation.

Ruef J, Nordt TK, Peter K, Runge MS, Kübler W, Bode C. Ruef J, et al. Thromb Haemost. 1999 Jul;82(1):109-14. Thromb Haemost. 1999. PMID: 10456463

5

Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase.

Moser M, Nordt T, Peter K, Ruef J, Kohler B, Schmittner M, Smalling R, Kübler W, Bode C. Moser M, et al. Among authors: ruef j. Circulation. 1999 Nov 2;100(18):1858-64. doi: 10.1161/01.cir.100.18.1858. Circulation. 1999. PMID: 10545429 Clinical Trial.

6

Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.

Peter K, Kohler B, Straub A, Ruef J, Moser M, Nordt T, Olschewski M, Ohman ME, Kübler W, Bode C. Peter K, et al. Among authors: ruef j. Circulation. 2000 Sep 26;102(13):1490-6. doi: 10.1161/01.cir.102.13.1490. Circulation. 2000. PMID: 11004138

7

4-hydroxynonenal induces apoptosis, NF-kappaB-activation and formation of 8-isoprostane in vascular smooth muscle cells.

Ruef J, Moser M, Bode C, Kübler W, Runge MS. Ruef J, et al. Basic Res Cardiol. 2001 Apr;96(2):143-50. doi: 10.1007/s003950170064. Basic Res Cardiol. 2001. PMID: 11327332

8

Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells.

Ruef J, Moser M, Kübler W, Bode C. Ruef J, et al. Cardiovasc Pathol. 2001 Nov-Dec;10(6):311-5. doi: 10.1016/s1054-8807(01)00095-3. Cardiovasc Pathol. 2001. PMID: 11755377

9

Indications for the presence of an atypical protease-activated receptor on rat platelets.

Ruef J, Kacharava A, Pohl J, Bode C, Runge MS. Ruef J, et al. Ann Hematol. 2000 Nov;79(11):604-11. doi: 10.1007/s002770000211. Ann Hematol. 2000. PMID: 11131919

10

Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.

Moser M, Ruef J, Peter K, Kohler B, Gulba DC, Paterna N, Nordt T, Kübler W, Bode C. Moser M, et al. Among authors: ruef j. J Thromb Thrombolysis. 2001 Oct;12(2):165-9. doi: 10.1023/a:1012975522037. J Thromb Thrombolysis. 2001. PMID: 11729368 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters